29.04.2015 • NewsDede WillamsSanofidrug approval

EU Approves Sales of Sanofi’s New Diabetes Drug

The European Commission has granted marketing authorization in Europe for Sanofi's Toujeo, a next-generation basal insulin for the treatment of type 1 and type 2 diabetes mellitus in adults.

The Commission said its decision was based on results from the Edition clinical trial program, a series of worldwide Phase III studies evaluating the efficacy and safety of Toujeo compared with Lantus, another Sanofi product, in more than 3,500 adults with type 1 or type 2 diabetes.

Pierre Chancel, senior vice president, Global Diabetes, at Sanofi, said EU marketing authorization for Toujeo represents a "significant milestone" for the company, expanding its integrated portfolio of solutions for people with diabetes in Europe."

The marketing approval follows the Feb. 26 positive opinion issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

Toujeo also has been approved by the US Food and Drug Administration (FDA) and is under review by regulatory authorities in other countries.

Interview

Fostering Innovation and Collaboration
Specialty Chemicals Distributor IMCD’s Strategy

Fostering Innovation and Collaboration

Valerie Diele-Braun, CEO of IMCD, shares her vision for sustainability, global expansions, and strategic direction in an exclusive CHEManager International interview.

Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.